Skip to main content
Johnson & JohnsonPatent grant

Janssen Biotech was granted a patent for testing CAR immune-cell potency

Source: Autobound Signal API · 88 signals tracked for Johnson & Johnson · updated

Get Johnson & Johnson's live signals in Claude or ChatGPT, or by API

AskWhat changed at Johnson & Johnson this week? Use Autobound signals for jnj.com.

What happened

In November 2026 Janssen Biotech patented an in vitro assay for measuring tumor-cell killing by CAR-expressing immune cells in cancer research and therapy development.

Source

Abstract

The disclosure provides an in vitro method for determining potency (e.g., cytotoxicity) of an immune cell expressing a chimeric antigen receptor (CAR) molecule. In a test sample, CAR-expressing immune cells are incubated with target cells expressing an antigen which interacts with the CAR. In a control sample, the CAR-expressing immune cells are incubated with the target cells and an inhibitory molecule that prevents interaction between the CAR and the target cells. The amount of target cell death is determined in both the test sample and the control sample and is compared.

patents.google.com/patent/US12800572Read the full source

Extracted by Autobound

From the Signal API record
Signal
Patent grant

What this signalsA new patent often shows where a company is putting its R&D budget.

Grant date
Nov 17, 2026
Inventors
J. Kendall Williams
Patent number
US12800572
Assignee
JANSSEN BIOTECH, INC.

The full record

From the Signal API record

People

  • J. Kendall WilliamsInventor

Details

Primary CPC class
G01N 33/505
USPTO assignee
JANSSEN BIOTECH, INC.
What the invention does
A lab test that compares CAR immune cells attacking target cells with and without a blocking molecule to measure their cancer-killing strength.

Topics and mentions

Tags

  • Intellectual Property
  • Research & Development
  • Medical Research
  • Pharmaceuticals

Technologies named

  • CAR-T cell therapy
  • cell-based assay
  • cytotoxicity testing
  • immuno-oncology

Extraction

Detected
Nov 18, 2026
signal_type
patents-company
signal_subtype
patentGrant

Use this data

Get every patent signal for Johnson & Johnson and the companies you sell to, in the tools you already use.

  1. Ask Claude about it

    Connect Autobound to Claude, Claude Code or Cursor with MCP. Then ask: “What changed at Johnson & Johnson this week?”

  2. Send it to your own tools

    The Signal API returns patent signals for any list of companies as JSON, for your CRM, warehouse or app.

  3. Try it free

    Sign up and spend your free credits on the companies you sell to.

    Start Free1,000 free credits

The API returns more than this page shows

This page shows a preview. The full patents-company record in the Signal API and MCP can also have these 8 fields. Some fields are empty for some signals.

Company

  • linkedin_urlValue in the API
  • industriesValue in the API
  • employee_count_lowValue in the API
  • employee_count_highValue in the API
  • revenueValue in the API
  • descriptionValue in the API

Signal

  • signal_nameValue in the API
  • associationValue in the API
Show the full JSONThe record on this page and the API request

GET /v1/signals/2622b71b-9c76-582b-90e2-2fbbda0c441a returns this record as JSON. POST /v1/companies/enrich returns every signal for jnj.com.

{
  "signal_id": "2622b71b-9c76-582b-90e2-2fbbda0c441a",
  "signal_type": "patents-company",
  "signal_subtype": "patentGrant",
  "detected_at": "2026-11-18T15:20:45+00:00",
  "company": {
    "name": "Johnson & Johnson",
    "domain": "jnj.com"
  },
  "data": {
    "cpc": [
      {
        "code": "G01N 33/505"
      },
      {
        "code": "G01N 33/5017"
      }
    ],
    "tags": [
      "Intellectual Property",
      "Research & Development",
      "Medical Research",
      "Pharmaceuticals"
    ],
    "detail": "In November 2026 Janssen Biotech patented an in vitro assay for measuring tumor-cell killing by CAR-expressing immune cells in cancer research and therapy development.",
    "summary": "Janssen Biotech was granted a patent for testing CAR immune-cell potency",
    "event_at": "2026-11-17",
    "inventors": [
      {
        "name": "J. Kendall Williams",
        "status": "unresolved",
        "is_primary": true
      }
    ],
    "event_kind": "grant_date",
    "grant_date": "2026-11-17",
    "source_url": "https://patents.google.com/patent/US12800572",
    "cpc_primary": {
      "code": "G01N 33/505"
    },
    "patent_title": "Cell-based assay for determining the in vitro tumor killing activity of chimeric antigen expressing immune cells",
    "patent_number": "US12800572",
    "uspto_assignee": "JANSSEN BIOTECH, INC.",
    "patent_abstract": "The disclosure provides an in vitro method for determining potency (e.g., cytotoxicity) of an immune cell expressing a chimeric antigen receptor (CAR) molecule. In a test sample, CAR-expressing immune cells are incubated with target cells expressing an antigen which interacts with the CAR. In a control sample, the CAR-expressing immune cells are incubated with the target cells and an inhibitory molecule that prevents interaction between the CAR and the target cells. The amount of target cell death is determined in both the test sample and the control sample and is compared.",
    "precision_class": "structural",
    "invention_explanation": "A lab test that compares CAR immune cells attacking target cells with and without a blocking molecule to measure their cancer-killing strength.",
    "technologies_mentioned": [
      "CAR-T cell therapy",
      "cell-based assay",
      "cytotoxicity testing",
      "immuno-oncology"
    ]
  }
}

Long text fields are shortened on this page.

Looking up one signal by its id is free. Enrich costs 2 credits per signal returned; a call with no results is free.